Finally, some good news as Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited have announced their intention to start a Phase III clinical trial of TAK-700 in the U.S. for men with advanced prostate cancer. TAK-700, which I have been writing about under the heading of “On the Horizon,” is [...]
Today, I spent most of the day listening to the CME (Medicare & Medicaid) hearing on Provenge. CME does not have to abide to the decisions of the advisory committee, so like we experienced with the FDA Advisory Committees we will have to wait and see what will eventually become the policy for reimbursement. I [...]
Taking supplements can become confusing. First we hear that a product will help us, it will control our PSA or maybe even cure our cancer. Certain supplements come into vogue; you can’t beat the disease without taking them, almost take them or be square. Then we hear that the product does nothing. It is confusing. [...]
There has been a lot of controversy over the association between obesity and the eventual biochemical failure of men treated for prostate cancer. Research performed at the Cleveland Clinic, Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio attempted to determined whether there is an association between body mass index and biochemical failure [...]
Since the approval of Provenge in April of 2010 the pipeline of new potential immunotherapy drugs has swelled. For excellent reasons, many of us are very optimistic about the future. […]